Install
Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t
- 30articles · 30d
- 13+ hour agolatest article
- Aug 17, 2026earliest in window
- 97%with images
- 336avg words
- Medical 23
- Health & Wellness 20
- Health 13
- Economy, Business & Finance 11
- Business & Industrial 6
- Science & Technology 5
- Finance & Business 4
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Avecho moves to deepen global partnering push as CBD insomnia program advances - Biotech
2+ week, 6+ day ago (418+ words) Avecho Biotechnology has appointed senior pharmaceutical executive Eve Williamson as a strategic business development consultant, bringing dedicated dealmaking capacity as the company seeks international partners for its CBD TPM soft-gel capsule for insomnia. The appointment comes as Avecho advances its…...
Mesoblast completes treatment in pivotal low back pain trial as phase 3 readout approaches
3+ week, 6+ day ago (340+ words) Mesoblast has completed treatment of all 350 patients in its pivotal phase 3 trial of rexlemestrocel-L for chronic low back pain caused by inflammatory degenerative disc disease, putting the company on track for top-line results in mid-2027. The trial, known as MSB-DR004, is…...